Skip to content Skip to footer

Unveiling FDA Acceptance: Ahsan Arozullah of Astellas Dives into Insights on PADCEV sBLAs for UC patients

Shots: Ahsan spoke about the US FDA acceptance for Priority Review of sBLAs for PADCEV and KEYTRUDA to treat patients with LA/mUC who are not eligible to receive cisplatin-containing CT He also talked about the study design and outcomes from the P-Ib/II (EV-103) clinical trial that supported the sBLA. The results from Dose Escalation/Cohort A…

Read more

Insights+: Key Takeaways of J.P. Morgan Healthcare Conference 2023 Based on Therapeutic Areas

Insights+: Key Takeaways of J.P. Morgan Healthcare Conference 2023 Based on Therapeutic Areas

Shots: The 41st Annual J.P. Morgan Healthcare Conference took place on 09 – 12 January 2023 in San Francisco, CA, USA. It is the largest and most informative healthcare investment symposium in the industry, bringing together a cohort of industry leaders, emerging fast-growing companies, innovative technology creators, and members of the investment community  The major announcement…

Read more

John Strickler, Associate Professor of Medicine, Duke University School of Medicine, Shares Insights from the P-II Study at the 2022 ESMO World Congress on Gastrointestinal Cancer

John Strickler, Associate Professor of Medicine, Duke University School of Medicine, Shares Insights from the P-II Study at the 2022 ESMO World Congress on Gastrointestinal Cancer

Shots: John spoke about the results from the P-II MOUNTAINEER Trial evaluating its lead candidate in mCRPC He also talked about TUKYSA (tucatinib) in combination with trastuzumab as a potential treatment for mCRPC The interview gives a deeper understanding of Seagen’s vision of developing transformative cancer treatment options Smriti: Share the details (ROA, MOA & formulations)…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]